Literature DB >> 11122721

Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

A Faggiotto1, R Paoletti.   

Abstract

The inhibition of cellular proliferation, the restoration of endothelial activity, the inhibition of platelet reactivity, and an antioxidant potential are only a few examples of pleiotropic effects of statins. This review analyzes the current knowledge on the pleiotropic properties of this class of drugs and examines the relevant data that support the presence of these effects in vivo. The favorable outcome of major trials of statins has indicated that pleiotropic factors indeed play a role in cardiovascular protection. In addition, recent data indicate that many pleiotropic effects influence mechanisms that belong to the extravascular compartment, as well. Perhaps, some of these properties may eventually justify additional indications for statins and improve the treatment of other diseases, including inflammation and cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122721     DOI: 10.1007/s11883-000-0091-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  58 in total

1.  Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products.

Authors:  J Kreuzer; J Bader; L Jahn; M Hautmann; W Kübler; E Von Hodenberg
Journal:  Atherosclerosis       Date:  1991-10       Impact factor: 5.162

Review 2.  Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.

Authors:  B A Hamelin; J Turgeon
Journal:  Trends Pharmacol Sci       Date:  1998-01       Impact factor: 14.819

3.  Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin.

Authors:  A Corsini; F Pazzucconi; P Pfister; R Paoletti; C R Sirtori
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

4.  Lovastatin prevents development of hypertension in spontaneously hypertensive rats.

Authors:  J Jiang; R J Roman
Journal:  Hypertension       Date:  1997-10       Impact factor: 10.190

5.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

6.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

7.  A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme.

Authors:  J Larner; J Jane; E Laws; R Packer; C Myers; M Shaffrey
Journal:  Am J Clin Oncol       Date:  1998-12       Impact factor: 2.339

8.  Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration.

Authors: 
Journal:  Lancet       Date:  1995 Dec 23-30       Impact factor: 79.321

Review 9.  New insights into plaque stabilisation by lipid lowering.

Authors:  P Libby; M Aikawa
Journal:  Drugs       Date:  1998       Impact factor: 9.546

10.  Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.

Authors:  J Dimitroulakos; D Nohynek; K L Backway; D W Hedley; H Yeger; M H Freedman; M D Minden; L Z Penn
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

View more
  2 in total

Review 1.  Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms.

Authors:  A S Callahan
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

2.  Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx.

Authors:  R Datar; W H Kaesemeyer; S Chandra; D J Fulton; R W Caldwell
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.